RxDoctor Payments Data

Bhumit Patel, MD

Family Medicine · Sturgis, MINPI 1144457722

Payments from drug & device makers

$486in general payments, 2019–2025

Across 28 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$83
  • Astellas Pharma US Inc$65
  • AstraZeneca$57
  • Novo Nordisk$55
  • Novartis$36
  • Johnson & Johnson$31
  • plus $158 from 8 others

What the payments were for

  • Food & beverage$47197%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$486 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$130,612
Medicare patients
426
Services billed
2,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$136,222
Trelegy ElliptaFluticasone/Umeclidin/Vilanter116$116,239
EliquisApixaban214$114,230
TrulicityDulaglutide83$100,896
JanuviaSitagliptin Phosphate81$65,069
JardianceEmpagliflozin45$48,767
XareltoRivaroxaban29$35,044
Breo ElliptaFluticasone/Vilanterol59$27,245
Nurtec OdtRimegepant Sulfate24$25,321
FarxigaDapagliflozin Propanediol25$22,033
MounjaroTirzepatide20$20,187
MyrbetriqMirabegron27$18,485
Tresiba Flextouch U-100Insulin Degludec25$16,343
Atorvastatin Calcium847$10,838
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$10,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$83$139,551238 claims
Novo NordiskOzempic$55$136,22296 claims
MerckJanuvia$11$65,06981 claims
Boehringer IngelheimJardiance$28$48,76745 claims
Johnson & JohnsonXarelto$31$35,04429 claims
AstraZenecaFarxiga$57$22,03325 claims
Astellas Pharma US IncMyrbetriq$65$18,48527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Sturgis

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →